Evaluation of the treatment costs and duration of topical treatments for multiple actinic keratosis based on the area of the cancerization field and not on the number of lesions.
Administration, Topical
Aminolevulinic Acid
/ analogs & derivatives
Cohort Studies
Cost of Illness
Diclofenac
/ economics
Diterpenes
/ economics
Drug Administration Schedule
Female
Fluorouracil
/ economics
Health Care Costs
Humans
Imiquimod
/ economics
Italy
Keratosis, Actinic
/ drug therapy
Male
Photochemotherapy
/ methods
Precancerous Conditions
/ drug therapy
Retrospective Studies
Risk Assessment
Severity of Illness Index
Treatment Outcome
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
03
07
2018
accepted:
19
09
2018
pubmed:
6
10
2018
medline:
7
6
2019
entrez:
6
10
2018
Statut:
ppublish
Résumé
The cost of topical treatments for actinic keratosis (AK) has historically been evaluated in relation to the number of lesions requiring treatment or simply by the price of a single tube/sachet of the drug used. To demonstrate a new method of costing topical treatments in AK, which takes into account the actual cancerization area treated. In order to evaluate the actual cost of each treatment, the official approval status of the drug was used to estimate the amount of cream needed per one cm Areas which could be treated with a single tube/sachet of Metvix Changing treatment costing strategy in the management of multiple AKs towards costing per cancerization area instead of costing per lesion is a much more accurate representation of the 'real world cost' for AK.
Sections du résumé
BACKGROUND
BACKGROUND
The cost of topical treatments for actinic keratosis (AK) has historically been evaluated in relation to the number of lesions requiring treatment or simply by the price of a single tube/sachet of the drug used.
OBJECTIVE
OBJECTIVE
To demonstrate a new method of costing topical treatments in AK, which takes into account the actual cancerization area treated.
METHODS
METHODS
In order to evaluate the actual cost of each treatment, the official approval status of the drug was used to estimate the amount of cream needed per one cm
RESULTS
RESULTS
Areas which could be treated with a single tube/sachet of Metvix
CONCLUSION
CONCLUSIONS
Changing treatment costing strategy in the management of multiple AKs towards costing per cancerization area instead of costing per lesion is a much more accurate representation of the 'real world cost' for AK.
Substances chimiques
3-ingenyl angelate
0
Diterpenes
0
Diclofenac
144O8QL0L1
methyl 5-aminolevulinate
585NM85KYM
Aminolevulinic Acid
88755TAZ87
Imiquimod
P1QW714R7M
Fluorouracil
U3P01618RT
Types de publication
Comparative Study
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
312-317Subventions
Organisme : Galderma
Informations de copyright
© 2018 European Academy of Dermatology and Venereology.